Your account is not claimed yet. You can sign up with ORCID to claim your account.

Matthias Ocker (Matias Knuuttila)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Venues

Cancers

International journal of molecular sciences

Expert review of gastroenterology & hepatology

Cells

Boehringer Ingelheim Pharma GmbH and Co KG Biberach

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Boehringer Ingelheim Pharma GmbH and Co KG Biberach

Germany

Therapeutic Area Head Oncology :: Translational Medicine & Clinical Pharmacology

Publications

Mari I Suominen, Matthias Ocker, Christoph A Schatz, Andreas Schlicker, Jukka Vääräniemi, Birgitta Sjöholm, Esa Alhoniemi, Bernard Haendler, Dominik Mumberg, Sanna-Maria Käkönen, Arne Scholz
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. International journal of molecular sciences 24 (3) (2023)
Mari I Suominen, Matthias Ocker, Christoph A Schatz, Andreas Schlicker, Jukka Vääräniemi, Birgitta Sjöholm, Esa Alhoniemi, Bernard Haendler, Dominik Mumberg, Sanna-Maria Käkönen, Arne Scholz
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. International journal of molecular sciences 24 (3) (2023)
Mari I Suominen, Matthias Ocker, Christoph A Schatz, Andreas Schlicker, Jukka Vääräniemi, Birgitta Sjöholm, Esa Alhoniemi, Bernard Haendler, Dominik Mumberg, Sanna-Maria Käkönen, Arne Scholz
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. International journal of molecular sciences 24 (3) (2023)
Peter Ellinghaus, Daniel Neureiter, Hendrik Nogai, Sebastian Stinzing, Matthias Ocker
Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End? Cells 11 (19) (2022)
Dino Bekric, Matthias Ocker, Christian Mayr, Sebastian Stinzing, Markus Ritter, Tobias Kiesslich, Daniel Neureiter
Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers 14 (7) (2022)
Christian Mayr, Tobias Kiesslich, Dominik Paul Modest, Sebastian Stintzing, Matthias Ocker, Daniel Neureiter
Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned? Expert opinion on investigational drugs 31 (2) (2022)
Matthias Ocker, Christian Mayr, Tobias Kiesslich, Sebastian Stinzing, Daniel Neureiter
Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers 13 (7) (2021)
Matthias Ocker, Daniel Neureiter
Predicting the outcome of patients with hepatocellular carcinoma: new approaches beyond established clinical scoring systems. Expert review of gastroenterology & hepatology 15 (2) (2020)
Andreas Schneeweiss, Dagmar Hess, Markus Joerger, Andrea Varga, Stacy Moulder, Apostolia M Tsimberidou, Cynthia Ma, Sara A Hurvitz, Christine Rentzsch, Marion Rudolph, Silke Thiele, Oliver Boix, Gary Wilkinson, Eleni Lagkadinou, Matthias Ocker
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers 11 (12) (2019)

Matthias Ocker.css-eqlu8i{font-size:small;padding-left:4px;} (Matias Knuuttila)

Publication Activity (10 Years)

Top Topics

Top Venues

Matthias Ocker (Matias Knuuttila)